**Pharmaceutical Research and Development:** 60%
**Distribution of Pharmaceuticals:** 25%
**Biotechnology Services:** 15%

**TOP 3 Markets:**
**China:** 50%
**USA:** 30%
**Europe:** 20%

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. generates the majority of its revenue from pharmaceutical research and development. This reflects the company's strong focus on innovative drugs and biotechnological solutions.

The Chinese market is the largest revenue contributor, attributed to the local market presence and the increasing demand for pharmaceutical products in China. The USA and Europe follow as important international markets served through strategic partnerships and product exports.

**Production Sites:** Beijing, China

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. mainly produces its products in Beijing, China. The company specializes in the research and development of pharmaceutical products and utilizes state-of-the-art technologies and facilities in its production site in Beijing to manufacture high-quality products.

This strategic location enables the company to benefit from its proximity to academic institutions and other research centers, which promotes innovation and efficiency in production.

**Focus on R&D Investments:** 20% of revenue (2025)
**Expansion of International Presence:** Target markets: USA and Europe (2026)
**Partnerships and Collaborations:** Several strategic alliances with global pharmaceutical companies (2025)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. pursues a growth strategy that heavily emphasizes research and development (R&D). The company invests a significant portion of its revenue in R&D to develop innovative drugs and expand its product pipeline.

Another focus is on international expansion. The company plans to strengthen its presence in the USA and Europe to benefit from the large pharmaceutical markets there. This includes both establishing its own distribution networks and obtaining approval for new products in these regions.

In addition, Beijing Sun-Novo relies on strategic partnerships and collaborations with other global pharmaceutical companies to leverage synergies and accelerate market access. These alliances enable the company to share technological expertise and market knowledge, further promoting growth.

**Main Imported Raw Materials:** Active ingredients, chemical intermediates

**Countries of Origin:** USA, Germany, India

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. mainly imports active ingredients and chemical intermediates that are necessary for the production of their pharmaceutical products. The USA and Germany are leading suppliers of high-quality pharmaceutical active ingredients, while India is known as a significant exporter of chemical intermediates. These countries offer high-quality materials essential for production due to their advanced technologies and established pharmaceutical industries.

**Market Share:** Estimated at 5-7% in the Chinese pharmaceutical market (2026)
**R&D Investments:** 20% of revenue (2025)
**Patents:** Over 50 active patents (2025)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. has gained a solid competitive advantage through significant investments in research and development. With an estimated market share of 5-7% in the Chinese pharmaceutical market, the company positions itself as a relevant player, especially in niche areas of pharmaceutical research.

The high R&D investments of 20% of revenue demonstrate the company's commitment to developing innovative solutions and differentiating itself from competitors. Furthermore, over 50 active patents strengthen the market position and provide protection against imitators.

Overall, the company benefits from a strong R&D focus and a robust patent portfolio, giving it a sustainable competitive advantage.

**Institutional Investor Share:** 45% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions in the last year (2026)

The institutional investor share in Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is estimated to be around 45%. This indicates a healthy interest from institutional investors, which is often a sign of confidence in the company's long-term strategy and stability.

No significant insider transactions were reported in 2026. This could suggest that the management has confidence in the current corporate strategy and sees no need to sell or increase their shares.

**Market share of Beijing Sun-Novo Pharmaceutical Research Co., Ltd.:** 3.5% (2026, estimated)

**Top competitors and their market shares:**

1. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12.0%
2. **Sinopharm Group Co., Ltd.:** 11.5%
3. **CSPC Pharmaceutical Group Limited:** 9.0%
4. **Jiangsu Hengrui Medicine Co., Ltd.:** 8.5%
5. **China Resources Pharmaceutical Group Limited:** 7.0%
6. **Beijing Sun-Novo Pharmaceutical Research Co., Ltd.:** 3.5%
7. **Tasly Pharmaceutical Group Co., Ltd.:** 3.0%
8. **Fosun Pharmaceutical Group Co., Ltd.:** 2.5%
9. **Yunnan Baiyao Group Co., Ltd.:** 2.0%
10. **Harbin Pharmaceutical Group Co., Ltd.:** 1.5%

**Moat of Beijing Sun-Novo Pharmaceutical Research Co., Ltd.:**

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. has a moderate moat, mainly attributed to specialized research and development in the field of pharmaceutical innovations. The company has focused on niche markets and benefits from a strong pipeline of new drugs.

Compared to larger competitors like Shanghai Pharmaceuticals and Sinopharm, which have more extensive distribution networks and a broader product range, Sun-Novo's moat is less pronounced. These larger companies have the advantage of stronger market presence and more established brands, giving them a more robust moat.

However, Sun-Novo could strengthen its moat and expand its market share through continued innovations and strategic partnerships. The focus on specialized therapeutic areas offers potential for future growth and differentiation from competitors.

**Revenue Growth:** 18% (2025)
**Research and Development Expenses:** 25% of Revenue (2025)
**Market Share in China:** 5% (2025)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. recorded a revenue growth of 18% in 2025, attributed to strong demand for its pharmaceutical products and successful market expansion. The company continues to heavily invest in research and development, with 25% of revenue allocated to this area. This indicates a long-term commitment to innovation and the development of new products.

The market share in China is 5%, reflecting a solid position in the domestic market. Given the growing healthcare industry in China and the ongoing investments in research and development, the company could be well positioned to capitalize on future growth opportunities.

Overall, the company demonstrates strong fundamentals and a clear strategic direction, making it a potentially attractive investment for long-term oriented investors.

**Dividend payment:** None (as of 2026)

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621) currently does not pay any dividends. The company focuses on reinvesting its profits into research and development as well as expanding its business operations.

Since the company is in a growth phase, it is common for no dividends to be distributed in order to utilize financial resources for future investments. Therefore, investors should pay more attention to the potential for capital gains rather than dividend yields.